Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Oncology

Verastem Oncology's Return On Capital Employed Insights

Verastem Oncology (NASDAQ:VSTM) brought in sales totaling $2.60 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 2.92%, resulting in a loss of $16.96 million.

Benzinga

Merger Arbitrage Mondays – Bristol Myers (BMY) Acquires Third Point Therapeutics (TPTX)

Another week and another deal with big pharma buying out a development stage oncology company. Given the real synergies to be had through young companies partnering with big pharma to leverage their manufacturing expertise and distribution networks, regulators have allowed most of them to go through and they tend to…

Benzinga

Surface Oncology's Return On Capital Employed Overview

According to Benzinga Pro, during Q1, Surface Oncology (NASDAQ:SURF) earned $6.20 million, a 125.78% increase from the preceding quarter. Surface Oncology also posted a total of $30.00 million in sales, a 19380.52% increase since Q4.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Bristol Myers to Buy Turning Point Therapeutics in $4.1 Billion Oncology Deal

“With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile," said Bristol Myers CEO Giovanni Caforio.

The Street

5 Oncology Stocks Wall Street Predicts Will Rally 135% or More

The oncology industry is expected to grow considerably in 2022, driven by the rising occurrence of cancer in the U.S. population. Furthermore, increasing investments by biopharmaceutical companies and the government should fuel the industry's growth. Given the industry's bright growth prospects, Wall Street analysts expect the stocks of quality oncology…

StockNews.com

Chennai hospital launches centre for geriatric oncology

It was inaugurated by senior geriatrician V.S. Natarajan

The Hindu

BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate

BridgeBio Pharma Inc (NASDAQ:BBIO) has announced interim Phase 1 data from healthy volunteers, supporting the development of BBP-671 for pantothenate kinase-associated neurodegeneration (PKAN) and organic acidemias. BBP-671 is being developed as a potential therapy for diseases in which coenzyme-A (CoA) metabolism is deficient, including PKAN, propionic acidemia (PA), and methylmalonic acidemia (MMA).…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Why Elevation Oncology Stock Is Rising

Elevation Oncology Inc (NASDAQ: ELEV) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track designation to seribantumab for the tumor-agnostic treatment of advanced solid tumors that harbor NRG1 gene fusions.

Benzinga

Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm

Citius Pharmaceuticals Inc (NASDAQ:CTXR) plans to form a new company (NewCo) focused on developing and commercializing I/ONTAK. A Phase 3 trial was completed in December 2021, and a biologics license application (BLA) is being planned for submission in the second half of 2022. The Company's other pipeline assets, including Mino-Lok, would remain at…

Benzinga

Elevation Oncology Shares Gain On FDA Fast Track Designation For Seribantumab In Tumor-Agnostic Settings

Elevation Oncology, Inc. (NASDAQ: ELEV) received Fast Track designation from the Food and Drug Administration (FDA) for Seribantumab in tumor-agnostic settings for the treatment of advanced solid tumors that harbor NRG1 gene fusions.

Benzinga

GM virus that kills cancer injected into first patient in US trial

Lab tests saw new treatment shrink colon, lung, breast, ovarian and pancreatic tumours

Wales Online

Cannabis And Cancer Pain: Israeli Study Shows Medical Marijuana Effective, Nearly 50% Of Patients Stop Traditional Pain Meds

Medical marijuana can help those suffering from cancer-associated pain, as per a new Technion study published on Friday in Frontiers in Pain Research.

Benzinga

Cancer groundshot: Access to proven treatments must parallel development of new therapies

Where should investment be made today in order to save the maximum number of lives from cancer tomorrow? That is the underlying principle behind the “cancer groundshot” philosophy.

The Conversation

North East nurse tells how the death of her mum inspired her to become cancer specialist

'As a nurse your intuition is to comfort your patient, and working in these conditions made it unbelievably tough.'

Chronicle Live

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Menarini, Radius Health's Elacestrant Prolongs Progression Free Survival In Breast Cancer

The Menarini Group and Radius Health Inc's (NASDAQ: RDUS) data from the phase 3 EMERALD trial evaluating elacestrant for ER+/HER2- advanced or metastatic breast cancer were published in the Journal of Clinical Oncology.

Asharq Al-Awsat

Cancer Coalition Aims to Boost Access to Medicines in Poorer Countries

Pharmaceutical companies including Novartis and Roche have teamed up with global cancer organizations in an alliance aimed at getting more oncology medications to poorer countries. Currently, fewer than 50% of the cancer drugs on the World Health Organization's (WHO) essential medicines list are available in low and middle income countries,…

Benzinga

76 Biggest Movers From Yesterday

Gainers Bright Green Corp. (NASDAQ: BGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Green Corporation, went public on the NASDAQ Tuesday, becoming the first U.S. plant-touching company to list on a major U.S. stock exchange.

Benzinga

Sorrento Starts Mid-Stage Study Of Abivertinib In Prostate Cancer

The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ:SRNE) investigational new drug application (IND) for Abivertinib (Fujovee) for Phase 2 MAVERICK study in metastatic castrate-resistant prostate cancer (mCRPC). The MAVERICK study will be conducted in a partnership with the Prostate Cancer Clinical Trials Consortium and will enroll participants with both abiraterone-naïve and abiraterone-progressing…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Stocks That Hit 52-Week Lows On Monday

On Monday, 198 companies reached new 52-week lows.

Chronicle Live

More than 6,500 runners help raise almost 210,000 to help children with cancer in UK's biggest charity fun run

Almost £210,000 was raised for Children’s Cancer North after the UK's biggest charity fun run was held on Sunday at Gosforth Park

Daily Record

New cancer consultant signs up with NHS Tayside

It is hoped the positive news will ease pressure on the health board’s under-fire oncology department.

Benzinga

Why Are Cullinan Oncology Shares Rising Today?

Taiho Pharmaceutical Co Ltd will co-develop and co-commercialize Cullinan Oncology Inc (NASDAQ: CGEM) lead program, CLN-081/TAS6417.

Benzinga

BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology

BridgeBio Pharma Inc (NASDAQ:BBIO) has announced an exclusive license with Bristol Myers Squibb Co (NYSE:BMY) to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology. Under the agreement terms, BridgeBio will receive an upfront payment of $90 million, up to $815 million in development, regulatory and sales milestone payments, and tiered royalties in…

Liverpool Echo

Cancer nurse gives best care she can after personal tragedy with the illness

Stephanie is motivated to give the best care she can to her patients after experiencing personal tragedy

Benzinga

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

1 … 5 6 7 8

Organisations

World Health Organization

Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.